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E2F1 is a multi-faceted protein that has roles in a number of important cellular 
processes including cell cycle regulation, apoptosis, proliferation, and the DNA 
damage response (DDR).  Moreover, E2F1 has opposing roles in tumor 
development, acting as either a tumor suppressor or an oncogene depending on the 
context.  In human cancer, E2F1 is often deregulated through aberrations in the Rb-
p16INK4a-cyclin D1 pathway.  In these studies we examined three mechanisms by 
which E2F1 might mediate its tumor suppressive properties:  p21-induced 
senescence, miRNAs, and the DNA damage response.  We found that E2F1 acts 
as a tumor suppressor in response to ras activation through a non-apoptotic 
mechanism requiring ARF and p53, but not p21.  However, p21-loss inhibited two-
stage chemical carcinogenesis in FVB mice.  In response to E2F1 overexpression, 
we found that 22 miRNAs are differentially regulated in mouse epidermis, including 
let-7a, let-7c, and miR-301.  Additionally, regulation of miR-301 involves binding of 
E2F1 to its promoter.  Finally, our data indicate a role for E2F1 at sites of DNA 
 vi 
damage requiring E2F1’s phosphorylation at serine 31 which may involve DNA 
repair.  Further, this role in the DDR may affect tumor aggressiveness and 
multiplicity.  In all, we have explored three mechanisms for E2F1-induced tumor 
suppression and identified E2F1’s role in the DNA damage response as a likely 
contributor to this phenomenon. 
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Chapter 1:  Background and Introduction 
 2 
1.1 E2F1 and the E2F Family  
 
The E2F family is a group of transcription factors consisting of E2Fs 1-8 
along with three dimerization partners, DP 1, 2/3, and 4, reviewed in (1). Yet, there 
are nine E2F proteins in total because two forms of E2F3 are transcribed from 
alternate promoters, E2F3a and E2F3b (2, 3).  E2F1 was first identified as a cellular 
component that binds to the adenoviral E2 promoter (E2-binding factor), thus the 
name (4, 5).  Most members of the E2F family (E2F1-6) contain a DNA binding 
domain and a dimerization domain through which E2F proteins heterodimerize with 
one of three DP proteins to allow high affinity DNA binding to promoters (Figure 1.1) 
(6-10).  E2F7 and 8 bind DNA independent of DP (11-14).  As well, E2F1-3 contain 
a cyclin A/cdk2 binding domain important for cell cycle control, and E2F1-5 contain 
a pocket protein binding domain also important in cell cycle control as well as 
transcription.  Additionally, E2Fs 1-5 contain a marked box domain important in 
protein-protein interactions and, in the case of E2F1, apoptosis (15, 16).  In all, E2F 
family members are multi-faceted molecules with roles in cell cycle progression and 
proliferation, transcription, apoptosis, and an emerging role in the DNA damage 
response.  Consequently, many E2Fs, including E2F1, have been identified as key 
players in cancer development both as tumor suppressors and as oncogenes. 
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Figure 1.1.  The E2F family. The DNA binding domain (DBD) is indicated in light 
blue, and the dimerization domain is shown in pink.  The domains required for a 
cyclin A/cdk2 and Rb family member binding are shown in red and green, 
respectively.  Mouse homologs of human DP-2 are referred to as DP-3; and, 
several differentially spliced variants of DP2/DP3 exist that are not shown.  Also, 
there are two isoforms of E2F7 which differ in their C-terminus (not shown) (1).  
MB=marked box, cdk=cyclin-dependent kinase, DP=dimerization partner, 
Rb=retinoblastoma 
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1.2 E2F1 and Cell Cycle 
 
E2F1 functions as a regulator of the cell cycle and promotes entry of cells 
into S phase by transcriptionally regulating target genes.  E2F family members are 
intricately regulated through a series of protein-protein interactions, including 
binding by the pocket proteins Rb, p130, and p107 (17, 18).  When bound by 
hypophosphorylated Rb, E2F1 is transcriptionally inactive (19-21).  However, as Rb 
and other pocket proteins are phosphorylated by cyclin/CDK (cyclin-dependent 
kinase) complexes, E2F is released to activate genes important for cell cycle 
progression, such as cyclin E, dihydrofolate reductase (DHFR), and Cdc6 (cell 
division cycle 6) (21).  Positive regulation of CDK activity occurs through the cyclic 
expression and degradation of cyclins, while negative regulation occurs through two 
classes of CDK inhibitors, the Ink4a proteins and the Cip/Kip family, which includes 
p21 (22).  
 
1.3 E2F1 and Transcription 
 
E2Fs form active transcriptional factors through dimerization with DP 
proteins, which then bind canonical E2F recognition sites within promoters.  Yet, 
functionality as transcriptional repressors or activators is determined primarily by the 
E2F subunit.  The E2Fs have classically been divided into three classes:  activators 
(E2F1, 2, and 3a), repressors (E2F3b, 4, 5), and repressors independent of Rb 
family members (E2F6, 7, and 8) based on expression patterns (23) and structure.  
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However, it is becoming increasingly clear that this classification is over simplistic at 
best.  Many family members have been shown to both repress and activate 
transcription based upon the cellular context (1).  For example, besides its well-
documented role as a transcriptional activator of cell cycle related genes, E2F1 has 
been shown to repress an equal number of genes, as well (24-28).   
Regulation of transcriptional activity of E2Fs is primarily through the Rb 
family.  Pocket proteins block the transactivational domain of activator E2Fs, which 
prevent the transcription factor from recruiting the basal transcriptional machinery 
subunit, TFIID (29).  Additionally, this association prevents the recruitment of co-
activators such as ACTR, GCN5, TRAPP, Tip60, and p300/CBP (30-34).  E2F1, 
specifically, can be blocked from binding DNA through its interaction with Rb (35).  
As well, E2F-DP heterodimers can be converted to transcriptional repressors 
through the pocket protein-mediated recruitment of chromatin remodeling factors 
such BRM/BRG1, HDACs, DNMT1, CtIP, CtBP, SUV39H, PRMT5 and others (1, 
36-50). 
 
1.4 E2F1 and Apoptosis 
 
In addition to its ability to promote proliferation, E2F1 has unique properties 
when compared to most other E2F family members.  When over-expressed, E2F1 
has the capacity to efficiently induce apoptosis in vitro and in vivo in mice (23, 51, 
52).  Of the other E2F family members, E2F2, 3, and 4 can also promote apoptosis, 
although E2F3 may do so through E2F1 (53-58).  Apoptosis is especially important 
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for maintaining tissue homeostasis and because it can be deregulated in many 
cancers.  E2F1’s induction of apoptosis can be either in a p53-dependent or p53-
independent manner.  E2F1 can upregulate p53 protein levels by transcriptionally 
activating the tumor suppressor ARF, but ARF is not required for p53-dependent 
apoptosis by E2F1 (59).  Also, E2F1 overexpression can stimulate ATM 
transcription and autophosphorylation leading to p53 stabilization and apoptosis 
(60-62).  In p53-independent apoptosis, E2F1 up-regulates a homolog of p53 (p73), 
and this mechanism appears to play an important role in apoptosis induction in 
human tumor cell lines that have lost p53 (63).  E2F1 can also promote apoptosis 
through alternative routes, such as the activation of caspases and apoptosis 
associated factor 1 (Apaf1) (64, 65).   
 
1.5 E2F1 in Human Cancer 
 
As well as being able to promote apoptosis, E2F1 also distinguishes itself 
from most other members of the E2F family because it has both tumor suppressive 
and oncogenic properties.  In human cancer, numerous examples exist 
demonstrating E2F1’s dual nature.  Several cancer cell lines and primary tumors 
have amplifications in chromosome 20q, the location of E2F1.  These include 
prostate and leukemia cell lines, as well as the following tumor types: melanoma, 
cervical, esophageal, and colon cancer (66-71).  Moreover, many cancers have 
increased levels of E2F1 expression, though this may be a consequence of Rb 
pathway deregulation.  This includes colorectal, lung, and breast cancer (72-74).  
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Finally, increased E2F1 expression is correlated with a worse outcome in some 
cancer types (74).  All of this points to E2F1 acting as an oncogene in human 
cancer.  On the other hand, some tumor types (bladder, colon, and B-cell 
lymphoma) are more aggressive when E2F1 expression is low, indicating the 
possibility that E2F1 is acting as a tumor suppressor in these cancers (75-78). 
 
1.6 E2F1 as an Oncogene 
 
E2F1 has oncogenic properties both in vitro in cell culture, and in vivo in 
mouse models.  NIH 3T3 cells and rat embryo fibroblasts were induced to form 
colonies with E2F1 overexpression, indicative of transformation (79, 80).  As well, 
cells expressing an E2F1 mutant incapable of Rb inhibition formed tumors in nude 
mice (80).  In vivo, post-mitotic lense fiber cells are stimulated to re-enter the cell 
cycle upon transgenic E2F1 expression, though p53 stimulates apoptosis of these 
cells (56).  Further, expression of E2F1 in megakaryocytes blocks the differentiation 
of these cells into platelets leading to severe thrombocytopenia and accumulation of 
megakaryoctes (81).  These examples highlight the proliferative potential 
associated with E2F1 overexpression.  Additionally, several mouse models 
demonstrate the oncogenic potential of E2F1.  In K5 E2F1 transgenic mice, which 
overexpress E2F1 in the skin and other keratin 5-expressing tissues, spontaneous 
tumors develop in the skin, vagina, forestomach, and odontogenic epithelium (82).  
In the context of p53 loss, this tumorigenesis is accelerated (23).  In a transgenic 
model where E2F1 is expressed in the liver, all mice develop adenomas of the liver 
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by 10 months of age, with some developing hepatocellular carcinomas by one year 
(83).  Finally, E2F1 expression in testes has complex consequences.  Constant 
E2F1 expression leads to massive apoptosis and testicular atrophy, while a short 
exposure to E2F1 still causes apoptosis, but also dysplastic changes resembling 
carcinoma in situ (83, 84).  Thus, E2F1 has clear oncogenic properties that seem to 
vary depending on cellular context. 
   
1.7 E2F1 as a Tumor Suppressor  
 
Besides its oncogenic potential, E2F1 has also been demonstrated to 
function as a tumor suppressor.  In contrast to a report by Xu and colleagues 
mentioned previously, Lee et al. found that E2F1 inhibited the growth of NIH 3T3 
cells in response to Ras (79, 85).  In addition, transformation of keratinocytes by 
HPV E6 and E7 was inhibited by high E2F1 levels, but not lower levels (86).  This 
again points to the importance of cellular context and perhaps oncogenic stimuli in 
determining the effects of E2F1.  Similar results are seen in mouse models.  E2F1 
knockout mice have an increased incidence of thymic lymphomas and reproductive 
tract tumors, indicative of a role in tumor suppression by E2F1 (87, 88).  Moreover, 
E2F1 loss in Rb heterozygous mice predisposes these mice to some tumor types, 
while protecting them from others (89).  Additionally, K5 E2F1 overexpressing mice 
are resistant to two-stage skin carcinogenesis (82).  Together, these models 
demonstrate the dual nature of E2F1 as both an oncogene and tumor suppressor, 
and give clues to the molecular switch involved in this process, which seems to 
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depend on cellular context, E2F1 expression levels, timing, and genetic 
environment.  
 
1.8 Multi-Stage Carcinogenesis Assay 
 
The mouse two-stage carcinogenesis assay, or multi-stage carcinogenesis 
assay, consists of three well-defined stages that encompass consistant changes 
leading to carcinogenesis.  This assay is often used to model epithelial-type tumors.  
The three steps of this multi-stage model include:  initiation, promotion, and 
progression.  The first step involves application of a single dose of a genotoxic 
agent, typically the polycyclic aromatic hydrocarbon 7, 12-
dimethylbenz[a]anthracene (DMBA), to the shaved dorsal skin of mice.  After 
metabolism to its ultimate carcinogen, covalent binding of the electrophile to DNA 
results in an AT transversion in codon 61 of the Ha-ras gene, leading to a 
constitutively active protein (90, 91).  Promotion involves repeated application of a 
non-mutagenic, inflammatory agent such as TPA (O-tetradecanoyl-phorbol-13-
acetate) to the skin.  Addition of TPA to mouse skin results in synchronized 
proliferation of basal keratinocytes with concomitant gene expression characteristic 
of S phase (92).  This typically results in hyperplasia and may be accompanied by 
epigenetic changes that allow the clonal expansion of initiated cells and results in 
the formation of benign exophytic lesions called papillomas.  This step is required, 
as a single application of DMBA alone does not result in skin carcinogenesis.  
Moreover, promotion is reversible and papillomas will often regress.  Finally, the last 
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stage, progression, involves the accumulation of genetic changes leading to the 
conversion of a subset of papillomas into malignant squamous cell carcinomas 
characterized by invasion of the basement membrane and metastasis (93). 
 
1.9 K5 E2F1 Transgenic Model 
 
Since the Rb-p16INK4a-cyclin D1 pathway is the most mutated pathway in 
human cancer, and this pathway controls activity of the E2F family members, it was 
reasoned that an in vivo model for deregulation of this pathway could be made by 
overexpressing E2F1.  Though some might argue that a transgenic mouse that 
overexpresses a protein at a very high level may not be physiological, there is much 
evidence to the contrary.  This evidence includes data from the mouse as well as 
human studies.  During the two-stage carcinogenesis assay in the mouse, E2Fs 1-
5, have all been shown to be upregulated in tumors as compared to normal skin 
(94, 95).  In addition, high levels of E2F1 have been found in many human tumors 
including those from breast, pancreas, thyroid, esophagus, lung, colon, and bladder 
(73, 96-102); and, these levels tend to correlate with increased tumorigenicity and 
decreased disease-free survival.  Additionally, the E2F1 gene is amplified in a 
subset of gastric and colorectal carcinomas (73).  Though these high levels of E2F1 
protein may be only a consequence of tumorigenesis and not causative, the issue 
warrants further study. 
Thus, a transgenic mouse was generated using a construct containing the 
bovine (K5) keratin 5 promoter, human E2F1 cDNA, the rabbit –globin intron and 
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the SV40 polyadenylation signal (52).  This construct directs expression of E2F1 to 
the basal layer of the epidermis as well as other epithelial tissues.  Two lines were 
generated, line 1.0 and line 1.1, both with different expression levels.  At the RNA 
level, the two lines differ by 3-4 fold, with line 1.0 being the highest expressing line; 
the protein levels were estimated to be 80 and 50- fold above wildtype level by 
Western blot for line 1.0 and line 1.1 respectively (52).  The lower expressing line, 
1.1, will be used for all experiments.   
Phenotypic characteristics of the K5 E2F1 transgenic mouse include 
epidermal hyperplasia, hair loss, and increased epidermal apoptosis as compared 
to wildtype mice (52).  These mice also develop spontaneous tumors of the skin, 
vagina, forestomach, and odontogenic epithelium (82).  Moreover, K5 E2F1 
overexpression cooperates with a v-Ha-ras transgene to induce papilloma 
formation, as does loss of p53 (23, 52).  However, K5 E2F1 mice are resistant to a 
classic chemical carcinogenesis protocol driven by ras activation (82). 
 
1.10 Physiological Relevance of Tumor Studies in the K5 E2F1 Transgenic Model  
  
Several experiments have been completed to date that shed light on E2F1’s 
role in tumor development in the mouse skin.  As mentioned previously, using the 
K5 E2F1 transgenic model, our lab has shown that E2F1 is tumor suppressive when 
mice were subjected to a two-stage carcinogenesis protocol including DMBA and 
TPA (103).  Though the physiological relevance of this model has been called into 
question, recent studies offer support for the validity and study of E2F1 
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overexpression in the skin.   In a report using a skin-specific conditional knockout of 
Rb, Rb -/- mice developed less tumors than Rb +/+ mice when subjected to a two-
stage protocol.  Furthermore, when E2F1 was analyzed by Western blot, its levels 
were increased in the tumors arising from Rb-/- mice as compared to the wildtype 
controls (104).  Thus, these experiments suggest that Rb loss and E2F1 
overexpression in the skin may be acting similarly to result in tumor suppression in 
both models in response to activated H-ras.  Moreover in vitro studies using mouse 
cells and human cancer cell lines demonstrate that Rb is required for transformation 
by H-ras (105).  In fact, tumors that activate the ras pathway almost never contain a 
mutation in the Rb gene.  This lends additional support to the idea that E2F1 
overexpression, a consequence of Rb inactivation, can be tumor suppressive in the 
context of an activated H-ras protein and is physiologically relevant. 
 
1.11 K5 Myc Transgenic Model 
 
 The transcription factors Myc and E2F1 have many similarities.  Both 
proteins regulate genes important for cell cycle progression; and both can induce 
apoptosis, principally dependent on p53.  Additionally, Myc and E2F1 can transform 
rodent cells that have been immortalized or in cooperation with ras.  And finally, 
deregulated expression of either protein can lead to spontaneous tumorigenesis 
(106).  To further explore these similarities and possible differences with E2F1, we 
generated the K5 Myc transgenic mouse. 
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The K5 Myc transgenic mouse model was generated in much the same way 
as the K5 E2F1 transgenic mouse.  Briefly, a genomic murine c-myc fragment 
containing the entire Myc coding region was cloned into a vector under the control 
of the bovine K5 promoter with the rabbit -globin intron 2 and the SV40 
polyadenylation signal.   A total of three K5 Myc transgenic lines were generated, 
MM1, MM3, and MM5.  The level of c-myc overexpression for each line is 3.7-fold, 
6.0-fold, and 2.8-fold, respectively, by northern blot (106).  The lowest expressing 
line, MM5, will be used for all experiments.  
 The K5 Myc transgenic mouse has similar phenotypic characteristics to the 
K5 E2F1 mouse.  These mice display epidermal hyperplasia, increased proliferation 
and apoptosis in the skin, as well as hair loss.  Spontaneous lesions in the K5 Myc 
mouse include: ameloblastomas, squamous cell carcinomas, papillomas, and 
odontogenic tumors (106).  Inactivation of E2f1 or p53 enhances spontaneous 
tumorigenesis in response to K5 Myc (106, 107).  Conversely, loss of cyclin-
dependent kinase 4 (Cdk4) inhibits K5 Myc-induced tumors, pointing to a role for 
proliferation in spontaneous tumor formation driven by K5 Myc (108).  In contrast to 
K5 E2F1 mice, the K5 Myc mice are not resistant to two-stage chemical 
carcinogenesis, suggesting key differences between the functions of these two 
transcription factors. 
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Chapter 2: The Role of p21 and Senescence in Tumor 
Suppression by the E2F1 Transcription Factor 
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2.1 Abstract 
 
The transcription factor E2F1 has opposing roles in tumor development, acting as 
either a tumor suppressor or an oncogene depending on the context.  In human 
cancer the importance of E2F1 is demonstrated by the fact that it is targeted for 
deregulation in many cancer types through aberrations in the Rb-p16INK4a-cyclin D1 
pathway.  In order to study the role of E2F1 in tumorigenesis, our lab generated a 
transgenic mouse overexpressing E2F1 in the skin under the control of the keratin 5 
promoter (K5 E2F1).  We have since demonstrated that this mouse model is 
resistant to a classical chemical carcinogenesis protocol.  Further, additional tumor 
studies have indicated a requirement for both ARF and p53 in E2F1-mediated tumor 
suppression. Yet, the exact mechanism of E2F1’s tumor suppressive ability remains 
to be determined.  Subsequently, we have found that mice lacking ARF and 
overexpressing E2F1 have no significant difference in apoptosis when compared 
with mice on a wild type Arf background when both are treated with chemical 
carcinogens.  Additionally, untreated skin from mice overexpressing E2F1 and 
lacking ARF exhibits epidermal hyperplasia and reduced levels of p21 expression.  
Yet, when we crossed the K5 E2F1 transgenic mice onto a p21-null background, we 
found that loss of p21 in the skin enhances proliferation and apoptosis, but not 
hyperplasia.  Further, a two-stage carcinogenesis experiment shows that mice null 
for p21 are resistant to tumor development independent of the K5 E2F1 transgene.  
Additionally, data from our lab shows that K5 E2F1 mice lacking either ARF or p53 
have a decreased number of senescent cells in the epidermis when treated with a 
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short-term DMBA/TPA protocol; but no difference was seen in senescence-
associated -galactosidase (SA--gal) staining with or without p21.  In conclusion, 
we hypothesize that E2F1 acts as a tumor suppressor in response to Ras activation 
through a non-apoptotic mechanism requiring ARF and p53, but not p21. 
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2.2 Introduction 
 
To study the role of E2F1 in epithelial tumor development, our lab has 
previously generated a transgenic mouse expressing human E2F1 under the control 
of the keratin 5 promoter (K5 E2F1) (52).  In this model, we have found that E2F1 
can act as both a tumor suppressor and as an oncogene.  Overexpression of E2F1 
was found to increase hyperplasia, proliferation, and apoptosis in the epidermis, but 
did not block terminal differentiation (52).  K5 E2F1 activity alone induces 
spontaneous tumorigenesis in 50% of mice greater than 1 year of age with tumors 
arising in the skin, mouth, forestomach, vagina, and other K5-expressing tissues 
(82).  Additionally, E2F1 overexpression cooperates with the v-Ha-ras transgene to 
promote spontaneous papilloma development (52).  As well, loss of one or both 
copies of p53 enhances E2F1-induced spontaneous tumorigenesis in the skin, 
resulting in the formation of carcinomas (23).  In contrast to these findings, K5 E2F1 
mice are resistant to two-stage skin carcinogenesis, initiated by an activating ras 
mutation, and this is independent of the promotion agent used (82, 109). 
E2F1’s ability to suppress tumor formation in the K5 E2F1 model has 
subsequently been further explored.  Experiments from our laboratory indicate a 
requirement for both ARF (alternative reading frame) and p53 in this system as K5 
E2F1 transgenic mice lacking either gene are sensitive to a two-stage skin 
carcinogenesis protocol (109).  Moreover, K5 E2F1 mice lacking either ARF or p53 
have decreased numbers of senescent cells in the epidermis when treated with a 
short term DMBA/TPA protocol (Russell, unpublished data).  These findings, 
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together, point to senescence as a plausible mechanism for E2F1’s anti-tumor 
activity. 
Senescence is an irreversible exit from the cell cycle that may be induced by 
stresses such as oncogenes, oxygen radicals, telomere dysfunction, or other DNA 
damaging agents (110).  As well, senescence may be initiated through the activity 
of tumor suppressors or by chromatin remodeling (111).  Senescence was first 
identified almost 50 years ago as a phenomenon known as the “Hayflick Limit” 
which served as a barrier to infinite doubling of human fibroblasts in culture (112, 
113).  Two types or sub-classes of senescence exist, premature/cellular and 
replicative senescence.  Premature senescence differs from so-called replicative 
senescence because it does not involve the shortening of telomeres or misfunction 
of telomeric proteins (111, 114).   
Characteristic features of the senescence program include large, flat cells 
that are resistant to apoptosis and have altered gene expression patterns.  In 
particular, a common marker for senescent cells is the expression of senescence-
associated -galactosidase (SA--gal) activity when stained with X-gal (5-bromo-4-
chloro-3-indolyl B-D-galactopyranoside) at pH 6.0 (115).  SA--galactosidase 
activity has since been correlated with an increase in classic acid lysomal --
galactosidase enzyme activity due to an increase in the number of lysosomes found 
in senescent cells (116).  Other markers used to detect senescence include: p16, 
p15, p53, ARF, p21, SAHFs (senescence-associated heterochromatic foci), DEC1 
(deleted in esophageal cancer 1), and DCR2 (decoy receptor 2) (117). 
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Several genes have been reported to induce senescent-like phenotypes.  Of 
particular interest to us, the p19ARF/p53/p21Cip1 pathway has been implicated in 
senescence in many systems.  ARF is sufficient to induce senescence in both 
mouse and human fibroblasts (118, 119).  The tumor suppressor p53 can cause 
permanent cell cycle arrest possibly through increased DNA binding and 
transcriptional activity (111, 120, 121).  As well, p21, a downstream target of p53, 
has been implicated to play a major role in this phenomenon.  Levels of p21 are 
increased in senescent human fibroblasts and mouse keratinocytes, while p21-null 
mice have reduced age-related senescence and are less responsive to ras-induced 
premature senescence (122-124).  Moreover, overexpression of E2F1 in normal 
human fibroblasts induces senescence as evidenced by morphology, senescence 
associated -galactosidase (SA--gal) staining, and upregulation of the senescence 
associated genes, MMP-1 (matrix metalloproteinase-1), stromelysin, and PAI-1 
(plasminogen activator inhibitor-1) (119).  Furthermore, E2F1-induced senescence 
requires both ARF and p53 in this system (118, 119).   
Finally, this research is focused on exploring the possibility that E2F1-
induced senescence can suppress tumorigenesis in the mouse skin model.  We 
also want to discern the involvement of p21 in E2F1-mediated tumor suppression, 
given the fact that it is a major downstream target of p53; and, it has also been 
implicated in senescence. Thus, it is our hypothesis that E2F1 suppresses tumor 
formation by inducing senescence through a mechanism involving the cell cycle 
regulator, p21. 
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2.3 Materials and Methods                                                        
 
2.3.1 Mice:  Previously described K5 E2F1 transgenic mice generated by our lab 
(52) were maintained in the FVB line, ≥ 95% purity.  K5 E2F1 mice were crossed to 
p21-/- mice on an FVB background to generate K5 E2F1 mice that were 
heterozygous for p21.   F1 crosses of these mice were used to generate transgenic 
and non-transgenic littermates who were either wildtype or null for p21.  Genotyping 
was performed using sequence specific PCR primers. 
 
2.3.2 SA--gal Assay:  The -galactosidase assay was performed on dorsal mouse 
skin sections snap frozen in OCT (optimum cutting temperature) tissue matrix 
(Electron Microscopy Sciences, Hattfield, PA), sectioned, and mounted on glass 
sides.  SA--gal activity was detected using the Senescence Detection Kit 
(Biovision Research Products, Mountain View, CA).  Briefly, sections were washed 
with 1X phosphate buffered saline (PBS) and fixed for 15 minutes at room 
temperature with 0.5 ml of fixative solution.  After two 1X PBS washes, sections 
were stained in a solution containing 470 µl of staining solution, 5 µl of staining 
supplement, and 25 µl of 20 mg/ml 5-bromo-4-chloro-3-indolyl B-D-
galactopyranoside (X-gal), in dimethyl sulfoxide (DMSO) for 48 hours at 37°C.  After 
the development of blue color, sections were counterstained with nuclear fast red 
for 5 minutes at room temperature and coverslipped with Permount (Biomeda, 
Foster City, CA).  The number of senescent cells per 10 mm of epidermis was 
counted. 
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2.3.3 BrdU Incorporation:  Mice were injected with 170 µl of 20 mM 
bromodeoxyuridine (BrdU) and sacrificed 20 minutes later.  Dorsal skin was 
collected, fixed in formalin, paraffin-embedded, and sectioned. Skin sections were 
next de-paraffinized and hydrated, followed by blocking with 3% H2O2 (peroxide) in 
water for 10 minutes. After washing, antigen was retrieved with 10 mM citrate 
buffer, pH 6.0, for 10 minutes in a microwave oven followed by a 20 minute cool 
down. Slides were again washed and blocked using Biocare Blocking Reagent 
(BS966M, Biocare, Concord, CA) for 10 minutes. After an additional wash, slides 
were incubated with primary BrdU antibody (347580 (1:500), Becton Dickinson, 
Franklin Lakes, NJ) for 1 hour and 30 minutes at RT (room temperature).  Following 
two washes, slides were incubated with biotinylated rabbit-anti-mouse Fab’ 
(AXL5230M, Accurate Chemical and Scientific Corporation, Westbury, NY) for 15 
minutes at room temperature.  Slides were then washed 2x in buffer, and incubated 
with SA-HRP (streptavidin-horseradish peroxidase) (BioGenex Laboratories, Inc., 
San Ramon, CA) for 30 minutes at RT.  Buffer wash was repeated and slides were 
incubated with DAB (3,3-Diaminobenzidine tetrahydrochloride) (Sigma-Aldrich, St. 
Louis, MO) while monitoring.  Slides were again washed, and then counterstained, 
dehydrated, cleared, and coverslipped.  The number of BrdU-positive cells per 10 
mm of epidermis was counted.   
 
2.3.4 Caspase-3 Assay:  Dorsal skin was collected, fixed in formalin, paraffin-
embedded, and sectioned. After de-paraffinization and hydration, endogenous 
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peroxidase activity was blocked with 3% H2O2 in water for 10 minutes.  After 
washing and antigen retrieval in 10 mM citrate buffer, pH 6.0, for 10 minutes, 
sections were cooled for 20 minutes, washed, and incubated with a primary 
caspase-3 specific antibody (AF835, R&D Systems, Minneapolis, MN) for 30 
minutes at RT.  After washing, slides were incubated with a biotinylated goat-anti-
rabbit IgG (Vector Laboratories, Burlingame, CA) at a 1:500 dilution for 30 minutes 
at RT. Following two 5 minute washes, slides were incubated with SA-HRP 
(BioGenex Laboratories, Inc., San Ramon, CA) for 30 minutes at RT. Again, slides 
were washed twice for 5 minutes each time, and stained with DAB (BioGenex 
Laboratories, Inc., San Ramon, CA) for 2-3 minutes.    Finally, slides were washed, 
counterstained, dehydrated, cleared, and coverslipped for viewing.  The number of 
caspase-3-positive cells per 10 mm of epidermis was counted.     
 
2.3.5 p53 Immunohistochemistry: Skin sections were collected, fixed in formalin, 
paraffin-embedded, and sectioned.  After de-paraffinization and hydration, sections 
were blocked with 3% H2O2 in water for 10 minutes and then washed. Upon antigen 
retrieval in 10mM citrate buffer, pH 6.0, for 15 minutes in a microwave and 20 
minute cool down, slides were blocked with Biocare Blocking Reagent (BS966M, 
Biocare, Concord, CA) for 10 minutes.  Slides were then incubated with primary 
antibody (NCL-p53-CM5p (1:500), Novocastra, St. Louis, MO) for one hour at RT 
followed by two buffer washes.  Incubation with Envision labeled polymer, anti-
rabbit-HRP (horseradish peroxidase) (Dako, Carpinteria, CA) for 30 minutes at RT 
was performed followed by 5 washes.  Following a five minute incubation with DAB, 
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slides were washed, counterstained, dehydrated, cleared, and coverslipped.   The 
percentage of p53-positive cells was determined microscopically per 1000 basal 
cells. 
 
2.3.6 p21 Immunohistochemistry: Dorsal skin was collected, fixed in formalin, 
paraffin-embedded, and sectioned.  After de-paraffinization and hydration, sections 
were blocked with 3% H2O2 in water for 10 minutes.  After washing, antigen was 
retrieved with 1.0 mM EDTA (ethylenediaminetetraacetic acid), pH 8.0, for 10 
minutes in a microwave and cooled for 20 minutes.  Slides were blocked with 
Biocare Blocking Reagent for 10 minutes (BS966M, Biocare, Concord, CA).  Slides 
were then incubated with p21 primary antibody (sc-6246, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) at a 1:50 dilution O/N (overnight) at 4C.  
Following two washes, slides were incubated with biotinylated rabbit-anti-mouse 
Fab’ (AXL5230M, Accurate Chemical and Scientific Corporation, Westbury, NY) for 
15 minutes at room temperature.  Slides were then washed 5x in buffer, and 
incubated with SA-HRP (BioGenex Laboratories, Inc., San Ramon, CA) for 30 
minutes at RT.  Buffer wash was repeated and slides were incubated with DAB 
(Sigma-Aldrich, St. Louis, MO) while monitoring.  Slides were again washed, and 
then counterstained, dehydrated, cleared, and coverslipped.  The percentage of 
p21-positive cells per 1000 basal cells was determined microscopically. 
   
2.3.7 Two-stage Mouse Skin Carcinogenesis Assay:  Six- to eight-week old male 
and female mice were shaved 1-2 days prior to experiments.  Mice were initiated 
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with 50 nmol of 9,10-dimethyl-1,2-benzathracene (DMBA) in 200 µl of acetone 
applied topically to the dorsal skin.  For long-term studies, tumors were promoted by 
the twice-weekly application of 12-O-tetradecanylphorbol-13-acetate (TPA), 2 µg in 
200 µl of acetone.  For short-term studies, TPA was applied twice, three and six 
days after DMBA treatment and mice sacrificed 24 hours after the last treatment.  
Mice were housed with littermates and examined weekly for papilloma formation. 
 
2.4 Results 
 
 To investigate the mechanism of E2F1’s tumor suppressive abilities, we 
performed immunohistochemistry on K5 E2F1 transgenic skin for ARF, p53, and 
p21.  We found that K5 E2F1 mice have an increased percentage of epidermal cells 
positive for expression of ARF, p53, and p21 when compared to wild type mice 
(Figures 2.1 and 2.2).  Further, when K5 E2F1 mice were crossed onto an Arf-null 
background, p53 and p21 staining in the epidermis was reduced (Figures 2.1 and 
2.2).  Additionally, loss of Arf leads to an increase in epidermal thickness in K5 
E2F1 transgenic mice, but there is no effect on apoptosis following short-term 
carcinogen (DMBA/TPA) treatment (Figure 2.3) (109). 
Next we crossed the K5 E2F1 mice onto a p21-null background and 
examined the epidermis for differences in proliferation, hyperplasia, and apoptosis.  
In untreated mice, loss of p21 lead to increased proliferation, as measured by BrdU 
incorporation, whether or not E2F1 was overexpressed, though this change was not 
statistically significant.  Yet, this increase in proliferation did not lead to a 
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corresponding increase in hyperplasia.  In fact, animals null for p21 have decreased 
epidermal thickness as compared to corresponding control mice.  This is true in the 
absence or presence of E2F1 overexpression, though only significant in transgenic 
skin, p=0.017 (Figure 2.4).   
Conversely, the overexpression of E2F1 in p21-null mice does result  in 
increased epidermal thickness when compared with p21-null mice not 
overexpressing E2F1, p=0.043.  Moreover, treatment with a short-term DMBA/TPA 
protocol does not change the trends identified for p21 loss on proliferation or 
hyperplasia.  However, only the decrease in proliferation approaches significance, 
p=0.077 (Figure 2.5).  Finally, we examined the result of p21 loss on its upstream 
effector p53 and found no effect on p53 expression.  Nonetheless, apoptosis is 
increased in K5 E2F1 mice lacking p21, p=0.0009, as assayed by caspase-3 
activity (Figure 2.6). 
Previously, our lab has shown that K5 E2F1 transgenic mice are resistant to 
two-stage chemical carcinogenesis and this requires both ARF and p53 (109).  
However, since these experiments were done in an SSIN background, we needed 
to assess whether K5 E2F1 transgenic mice are resistant to two-stage chemical 
carcinogenesis on an FVB background before proceeding with experiments in this 
strain background.  So, we initiated 13 wildtype and 13 K5 E2F1 mice with DMBA 
and promoted twice weekly with TPA for 22 weeks; and mice were scored weekly 
for papilloma development.  Wild type mice were found to have an average of 3 
tumors per mouse compared to less than one tumor per mouse for K5 E2F1 mice, 
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thus establishing the resistance of the transgenic mice to chemical carcinogenesis 
in an FVB background (Figure 2.7).   
Next we assessed the effect of p21 loss on E2F1-mediated tumor 
suppression.  We found that K5 E2F1 mice lacking p21 were resistant to a chemical 
carcinogenesis protocol.  However, mice lacking p21, without the K5 E2F1 
transgene, were also resistant to two-stage skin carcinogenesis (Figure 2.8).  This 
result was unexpected and suggests a surprising requirement for p21 in skin 
papilloma development.  Unfortunately, this requirement precludes us from 
establishing a role for p21 upregulation in E2F1-mediated suppression of skin 
carcinogenesis. 
Finally, to address the possibility that senescence could be involved in tumor 
suppression by E2F1, we examined the skin of wildtype and K5 E2F1 transgenic 
mice for -galactosidase activity.  We found a high level of background staining in 
the FVB strain background as compared to epidermis from SSIN mice (Figure 2.9).  
Yet, it is unclear why this high level of -galactosidase activity exists in FVB 
epidermis.  As well, carcinogen treatment did not seem to affect -galactosidase 
activity the same way for each strain.  DMBA/TPA treatment increased the 
senescent cells in K5 E2F1 epidermis on an SSIN background, but senescent cells 
decreased in the same mice on an FVB background.  Lastly, we stained K5 E2F1 
epidermis with and without p21 for -galactosidase (Figure 2.10).  We could detect 
no difference in staining in the basal layer, hair follicle, or super basal layers.  In all, 
because of the high background staining we could make no definitive conclusions 
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about the role of senescence in E2F1-mediated tumor suppression using -
galactosidase activity as a marker. 
 28 
 
Figure 2.1. K5 E2F1 transgenic epidermis exhibits higher levels of ARF, p53 
and p21 positive cells.  Skin sections were taken from mice, fixed, and 
immunohistochemically stained for ARF (a, b, and c), p53 (d, e, and f), or p21 (g, h, 
and i). The genotypes were wild type (a, d, and g), K5 E2F1 transgenic (b, e, and 
h), or K5 E2F1 transgenic, ARF-/- (e, f, and i). Photographs were taken at 40x 
magnification (109).  
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Figure 2.2. Inactivation of Arf reduces expression of p53 and p21 in K5 E2F1 
transgenic epidermis.  (A) Skin sections from nontransgenic and K5 E2F1 
transgenic mice, with or without Arf, were immunohistochemically stained for p53.  
The average percentage of epidermal cells that stained positive for p53 was 
determined microscopically using samples from at least 5 mice for each genotype.  
(B) Skin samples from the same mice as in (A) were stained for p21 and the 
percentage of cells staining positive was determined microscopically and graphed.   
Bars represent standard error.  * indicates p<0.05 by t-test (109). 
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Figure 2.3.  Inactivation of ARF induces hyperplasia but does not affect 
apoptosis. (A) The average epidermal thickness was determined by taking 20 
random measurements of each dorsal skin sample from 5 mice of each genotype. 
(B) Skin sections were taken from three wild type, two ARF-/-, four K5 E2F1, and 
four K5 E2F1, ARF-/- mice after a short term DMBA/TPA protocol.   Skin sections 
were stained for activated caspase 3 as a marker of apoptosis and the average 
number of caspase positive cells per 10mm of epidermis is shown.  Bars represent 
standard error.  * indicates p<0.05 by t-test (109). 
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Figure 2.4.  Inactivation of p21 increases BrdU-positive cells but not 
hyperplasia in K5 E2F1 transgenic epidermis. (A) Skin sections from non-
transgenic and K5 E2F1 transgenic mice, either with or without p21 as indicated, 
were immunohistochemically stained for BrdU. The average percentage of 
epidermal cells that stained positive for BrdU was determined microscopically using 
samples from six mice for each genotype. (B) The average epidermal thickness was 
determined by taking 20 random measurements of each dorsal skin sample from 
the same mice as above.  Bars represent standard error.  * indicates p<0.05 by t-
test.   
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Figure 2.5.  Short term DMBA/TPA treatment increases proliferation but not 
epidermal skin thickness in K5 E2F1 transgenic mice lacking p21.  (A) Dorsal 
skin sections were collected and immunohistochemically stained for Ki67.  The 
number of Ki67-positive cells per 1000 basal cells was calculated. Percentages are 
averages from at least 3 mice per genotype. (B) The average epidermal thickness 
was determined by taking 20 random measurements of each dorsal skin sample 
from the same mice as above.  Bars represent standard error.  No significance 
differences were detected by t-test, p<0.05.  
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Figure 2.6.  Apoptosis increases in K5 E2F1 transgenic epidermis when p21 is 
lost, but p53 levels are unchanged. (A) Dorsal skin was collected after short-term 
treatment with DMBA/TPA.  Skin was stained for p53 and the number of p53-
positive cells per 1000 basal cells was determined microscopically.  At least three 
mice per genotype were analyzed. (B) Skin sections from the same mice as above 
were immunohistochemically stained for activated caspase 3.  The average number 
of positive cells per 10 mm of epidermis was calculated.  Bars represent standard 
error.  * indicates p<0.05 by t-test.  
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Figure 2.7. K5 E2F1 transgenic mice on an FVB background are resistant to 
two-stage chemical carcinogenesis.  Mice were shaved 1-2 days prior to 
treatment. Wildtype (n=13) and K5 E2F1 (n=13) transgenic mice were initiated with 
50 nmol DMBA at 6-8.5 weeks of age.  Beginning two weeks after initiation, mice 
were treated twice weekly with 2 g of TPA for 22 weeks.  Tumor formation was 
assessed weekly beginning 6 weeks after initiation and the average number of 
papillomas per mouse is plotted. 
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Figure 2.8.  Suppression of two-stage carcinogenesis by E2F1 does not 
require p21.  A total of 13 wildtype, nine p21-/-, nine K5 E2F1 transgenic, and 10 K5 
E2F1 transgenic p21-/- mice in the FVB background were initiated with 100 nmol of 
DMBA at 6-8 weeks of age.   Two weeks later, mice were treated with twice weekly 
applications of 2.0 g of TPA for 16 weeks and 4.0 g of TPA for another seven 
weeks. Mice were examined weekly for papilloma formation; and, the average 
number of papillomas per mouse is plotted.   
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          A  
                                       
         B 
Strain- 
Genotype AC/AC AC/TPA DMBA/AC DMBA/TPA 
SSIN-WT 7 3 11 8 
SSIN- 
K5 E2F1 7 7 1 20 
FVB-WT 135 175 121 139 
FVB-  
K5 E2F1 113 160 125 114 
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Figure 2.9.  FVB mice have a high level of -galactosidase positive 
background staining when compared to SSIN mice when both are treated with 
a short-term DMBA/TPA protocol. (A) K5 E2F1 skin on an SSIN background 
stained for -galactosidase activity. (B) Mice were initiated with 10 (SSIN) or 50 
(FVB) nmol of DMBA or vehicle (acetone).  Two days later, mice were treated with 
TPA or vehicle, and again two days after that.  Mice were sacrificed 24 hours 
following the last treatment and dorsal skin sections were preserved in OCT tissue 
matrix.  After sectioning, one to two mice per genotype (wildtype or K5 E2F1) and 
background strain (SSIN or FVB) were assayed for -galactosidase activity using 
the Senescence Detection Kit from Biovision.  The number of -galactosidase-
positive cells per 10mm of epidermis was determined microscopically.  
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Figure 2.10.  -galactosidase activity is not affected by p21 status in either 
wildtype or K5 E2F1 transgenic mice. Mice were subjected to a short-term DMBA 
protocol.  Dorsal skin was collected and embedded in OCT tissue matrix.  Skin 
sections were stained using the Senescence Detection Kit from Biovision.  (A) The 
total number of -galactosidase-positive cells in the basal, superbasal and hair 
follicle compartments were counted and averaged separately per 10 mm of skin.  
Three mice per genotype were analyzed.  (B) The total number of -galactosidase-
positive cells in the basal and superbasal epidermis and hair follicle were counted 
per 10 mm of skin and averaged together for three mice per genotype. 
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2.5 Discussion 
 
 In this study, we investigated the mechanism of E2F1-mediated tumor 
suppression using the K5 E2F1 transgenic mouse model.  Our lab previously 
showed that this mouse is resistant to two-stage chemical carcinogenesis and that 
both ARF and p53 are required for tumor suppression in this model using an SSIN 
genetic background (82, 109).  As a primary downstream target of p53 (125), we 
explored p21 as a likely candidate for a role in this process as well.  Using 
immunohistochemistry (IHC), we found that all three proteins, ARF, p53, and p21 
were upregulated in K5 E2F1 epidermis and this was dependent on Arf (Figure 2.1 
and 2.2).  Since loss of Arf did not affect apoptosis, we concluded that an alternate 
mechanism must be responsible for tumor suppression by E2F1 (Figure 2.3). A 
reasonable choice for that mechanism was senescence.  In fact, unpublished data 
from our lab shows increased -galactosidase activity in K5 E2F1 transgenic skin, 
an indicator of senescence.  Furthermore, this increase in senescence cells was 
lost in the absence of either Arf or p53, consistent with tumor experiments.  Since 
p21 is a common mediator of senescence, we asked the question whether p21-
induced senescence could be responsible for tumor suppression by E2F1.  We 
found that loss of p21 itself conferred resistance to DMBA/TPA induced tumor 
formation, thus preventing us from making any conclusions about p21’s involvement 
in E2F1-mediated tumor suppression.  Furthermore, we also could not determine 
the role of senescence in E2F1-mediated tumor suppression because no difference 
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was seen by SA--gal staining between p21-null skin and p21-null skin 
overexpressing E2F1. 
Three labs have previously reported on the role of p21 in skin 
carcinogenesis; yet, each used a different strain of mice and each has drawn a 
different conclusion.  Philipp et al. reported that loss of p21 did not change tumor 
incidence versus wildtype mice, but it did result in a higher incidence of less 
differentiated tumors (Black Swiss x 129 mixed background) (126).  Weinberg and 
colleagues described an enhanced propensity to form papillomas in p21 knockout 
mice, but no change in rate of malignant conversion (129/SvEv background) (127).  
And finally, Topley et al. showed loss of p21 led to sensitivity to chemical 
carcinogenesis, but at a lower rate than wildtype mice, and an increased rate of 
carcinoma formation (SENCAR x NIH Swiss mixed background) (128).  Our lab has 
now generated another unique finding in yet another genetic background of mice.  
Our data shows that in an FVB background, loss of p21 results in loss of sensitivity 
to a classical skin carcinogenesis protocol.  The mechanism for this result is 
unclear, but may be due in part to an increase in apoptosis seen in K5 E2F1, p21-/- 
mice, that seems to occur independent of p53 protein levels.  It is worth noting that 
had we done this experiment in a different background, such as SSIN as we used 
previously, it is likely that our results would have been different.  Thus, these 
experiments highlight the significance of genetic background in experimental design 
and the caution with which to interpret such data in the context of signaling 
pathways.  
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Chapter 3: E2F1-mediated regulation of miRNAs 
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3.1 Abstract 
 
 
MicroRNAs (miRNAs) are a class of noncoding RNAs that regulate protein 
expression by targeting messenger RNAs for degradation or by inhibiting protein 
translation.  MiRNAs play a key role in development and their importance in cancer 
formation is becoming increasingly apparent.  Research has shown that E2F1 can 
be regulated by miRNA expression, but whether E2F1 could in turn regulate 
miRNAs in the skin was unclear.  Thus, we chose to investigate the effect of E2F1 
on miRNA expression using the K5 E2F1 transgenic model.  By northern blot, we 
discovered that let-7 was expressed at higher levels in epidermis from K5 E2F1 
transgenic mice as compared to wildtype mice.  Further, when mouse skin was 
treated with DMBA and TPA, let-7 expression was found to increase.  Despite this, 
microarray data failed to confirm these observations, and in fact, showed let-7 to be 
higher in wildtype skin.  Several other miRNAs, 16 in total, were expressed at higher 
levels in wildtype skin than in K5 E2F1 transgenic epidermis, while 6 miRNAs were 
downregulated in E2F1 overexpressing skin.  Consistent with the microarray data, 
western analysis did not show a downstream effect on Ras protein levels, a target 
of let-7, in wildtype and E2F1 transgenic epidermis with and without carcinogen 
treatment.  Moreover normal human fibroblasts (NHF) and squamous carcinoma 
cells do not show any effect on Ras when both were infected with an E2F1 
adenovirus.  We were, however, able to show that E2F1 binds to the miR-301 
promoter by chromatin immunoprecipitation (ChIP).  In summary these data provide 
intriguing evidence that E2F1 is involved in miRNA regulation.
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3.2 Introduction 
 
 
 MicroRNAs (miRNAs) are a class of small (18-25 nt) non-coding RNAs which 
regulate protein expression (129).  These small RNAs were first discovered in the 
early 1990s in the nematode C. elegans, but have quickly become important as key 
regulators of an ever expanding list of biological pathways (130, 131).  The 
processes identified to date that are regulated by miRNAs include: differentiation, 
cell proliferation, apoptosis, development, hematopoiesis, immunity, metabolism, 
stem cell maintenance, and ultimately cancer development (132-140). 
 miRNAs are initially transcribed as long precursor molecules (pri-miRNAs) by 
RNA polymerases II and III (141, 142).  These pri-miRNAs are then processed by 
Drosha to generate pre-miRNAs, which can be transported to the cytoplasm by 
exportin 5.  Once in the cytoplasm, pre-miRNA duplexes are cleaved by Dicer to 
generate mature miRNAs, which can then be incorporated into the RISC (RNA-
Induced Silencing Complex) complex.  As part of the RISC complex, miRNAs can 
regulate protein expression in one of two ways.  Degradation of target messenger 
RNAs occurs by deadenylation; or, translation of target mRNAs is blocked at either 
the initiation or elongation steps.  Preference for degradation or translational 
inhibition is based on complementarity between the miRNA and its target mRNA, 
with perfect complementation favoring degradation and imperfect pairing supporting 
translational inhibition (143, 144).  Generally speaking, plant miRNAs tend to have 
complete sequence pairing, while most animal miRNAs interact with their targets 
through 5’ seed sequences consisting of only 6-8 nucleotides (145). 
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 Mounting evidence has shown a clear role for miRNAs in cancer.  The first 
direct connection between miRNAs and cancer was found in B-cell chronic 
lymphocytic leukemia (B-CLL) when it was demonstrated that miR-15a and 16-1 are 
deleted in half, and downregulated in a third, of all CLL cases (146).  Subsequently 
several miRNAs have been identified as tumor suppressors (let-7) or oncogenes 
(miR-17-92, miR-155, miR-21, miR-372/373) (147-151).  Moreover, nearly all types 
of tumors show some degree of deregulated expression of miRNAs (152). 
 Several crucial cellular pathways are regulated by miRNAs, including the  
Rb pathway, notoriously known for being mutated in cancers (153).  As key 
components of this pathway, the E2F transcription factors are direct targets of 
miRNAs.  miR-210 targets E2F3 in ovarian cancer, while E2F6 is regulated by miR-
193a in oral squamous cell carcinoma (154, 155).  Additionally, E2F1 and E2F3 are 
targets of miR-34a in colon cancer cells (156).  More recent studies have shown 
that E2F1 can in turn regulate miRNAs.  E2F1 overexpression appears to 
downregulate miR-93 and miR-106b in gastric cancer (157).  Furthermore, E2F1-3 
are involved in autoregulatory feedback loops with at least two oncogenic miRNA 
clusters, miR-17-92 and miR-106b-25 (157-160).  All of this points to an important 
link between miRNAs, E2Fs, and cancer. 
 Our lab formerly generated a transgenic mouse model, which overexpresses 
the human E2F1 gene under the control of the keratin 5 promoter.  This directs 
expression of E2F1 to the skin and other epithelial tissues (52).  As mentioned 
earlier, this K5 E2F1 mouse is resistant to a two-stage chemical carcinogenesis 
assay, which relies on an activating mutation in Ras for initiation (82).  The miRNA 
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let-7 is known to negatively regulate Ras, and consequently is down-regulated in 
tumors that have an activating Ras mutation (151).  Thus, we decided to determine 
if let-7 or other miRNAs are regulated by E2F1 in mouse epidermis and, if so, 
possibly involved in E2F1-mediated tumor suppression.  
 
3.3 Materials and Methods 
 
3.3.1 Mice:  Previously described K5 E2F1 transgenic mice generated by our lab 
(52) were maintained in the FVB line, ≥ 95% purity.  Male and female mice were 
housed with littermates.  Genotyping was performed using sequence specific PCR  
primers. 
 
3.3.2 RNA Isolation and Northern Blot:  Epidermis was either untreated or treated 
with DMBA and TPA.  Treatment consisted of one 50 µm dose of DMBA followed 3 
and 6 days later by two TPA treatments of 2 µg each.  Mice were sacrificed 24 
hours after the second TPA treatment.  Total RNA was isolated from wildtype and 
transgenic epidermis using 10 ml of TRI Reagent per mouse (Applied 
Biosystems/Ambion, Austin, TX).  Epidermis was chipped from frozen whole skin 
into liquid nitrogen and ground into a powder using mortar and pestle and then 
combined with TRI Reagent.  After purification, RNA was then run on a 15% 
acrylamide/urea gel, transferred to a positively charged nylon membrane and 
probed for either the let-7 miRNA (5’-aaccatacaacctactacctca-3’) or the U6 snRNA 
(5’-atttggttcgcttcacgaatt-3’).  Probes were labeled with dCTP using the Rediprime II 
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random prime labeling kit (GE Healthcare Biosciences, Pittsburgh, PA).  
Membranes were washed and exposed to Kodak BioMax MS film for imaging. 
Densitometry was performed using the StormTM Imager (GE Healthcare 
Biosciences, Pittsburgh, PA). 
 
3.3.3 Protein Isolation and Western Blot:  Epidermis was treated with acetone, 
acetone/TPA or DMBA/TPA.  Treatment consisted of a single 100 µm dose of 
DMBA in 200 l of acetone, followed 3 and 6 days later by two TPA treatments of 2 
g each in acetone.  Mice were sacrificed 48 hours after the second TPA treatment.  
Protein was isolated from either wildtype and transgenic epidermis or cells using 
modified RIPA buffer.  Protein was run on an 8% SDS/PAGE gel, transferred to a 
PVDF membrane using standard methods and assayed for either Ras (05-516, 
Millipore, Billerica, MA), -tubulin (sc-9104, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA), or actin (sc-8432, Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  The 
Ras antibody recognizes H-, K-, and N-Ras.  Membranes were washed and 
exposed to Kodak BioMax MS film for imaging.  Densitometry was performed using 
the StormTM Imager (GE Healthcare Biosciences, Pittsburgh, PA). 
 
3.3.4 Chromatin Immunoprecipitation:  Chromatin was isolated from NIH 3T3 
fibroblasts (CRL-1658, American Type Culture Collection, Manassas, VA) using 
standard methods and sheared by sonication.  ChIP was performed using the 
Upstate Biotechnology ChIP Assay kit (Millipore, Billerica, MA).  Antibodies were for 
E2F1 (sc-193, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit IgG 
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(ab46540, Abcam Inc., Cambridge, MA).  PCR was performed on 50 ng of each 
sample using a miR-301 specific primer pair (Forward:  5’-tcattggctgctgctgcttc-3’, 
Reverse:  5’-ttgacattcctcagaccgctg-3’). 
  
3.3.5 Microarray:  RNA was isolated from the epidermis of one wildtype and one 
K5 E2F1 transgenic mouse using 10 ml of TRI Reagent per mouse.  Epidermis was 
chipped from frozen whole skin into liquid nitrogen and ground into a powder using 
mortar and pestle.  After RNA isolation with TRI Reagent, further purification was 
done using RNeasy columns (QIAGEN, Valencia, CA) and a modified protocol.  
Briefly, 350 µl of RLT buffer was added to the RNA sample and vortexed.  Then, 3.5 
volumes of 100% ethanol were mixed with the sample and run through a column in 
700 µL aliquots, spinning for 15 seconds at ≥8000 x g.  Columns were washed with 
500 µL RPE buffer and eluted in RNase-free water.  RNA integrity was verified 
(RIN=7.8) and then analyzed using the Exiqon miRCURY LNA™ microRNA Array 
for all known human, mouse, and rat miRNAs (Vedbaek, Denmark).  
 
3.4 Results 
 
Our lab previously generated the K5 E2F1 transgenic mouse model, which is 
resistant to a two-stage chemical carcinogenesis protocol driven by an initiating 
mutation in H-ras (82).  Subsequently, reports have shown that Ras protein levels 
can be negatively regulated by the miRNA let-7 (151).  To study the possible role of 
miRNAs in E2F1-mediated tumor suppression in mouse epidermis, we examined 
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let-7 levels by northern blot.  We have found that let-7a & c expression was 
increased in K5 E2F1 epidermis as compared to wildtype skin (Figure 3.1).  This 
difference was 1.5-fold vs. 1.0 for let-7a and 1.7 fold vs. 1.0 for let-7c.  Moreover, 
treatment with chemical carcinogens (DMBA/TPA) increased this difference, 2.7-
fold vs.1.2-fold for let-7a and 3.0-fold vs. 1.8-fold for let-7c.  However, when western 
blots were conducted to look at the downstream effects of let-7 expression on Ras, 
ERK 1/2, and phospho-ERK protein levels, we found no significant differences in 
either mouse skin or cultured cells when E2F1 was overexpressed or not (Figures 
3.2, 3.3, and data not shown). 
To examine the global effect of E2F1 overexpression on miRNAs in mouse 
skin, we analyzed RNA from both wildtype and E2F1 transgenic epidermis for all 
known murine miRNA sequences using the Exiqon miRCURY LNA™ microRNA 
Array.  Microarray data showed several differences in miRNA expression between 
wildtype and K5 E2F1 skin.  miRNAs with 1-fold or greater difference in expression 
level are shown (Figure 3.4).  E2F1 seemed to upregulate miR-15a, 451, 331, 434-
3p, 195, and 300 as compared to wildtype, while let-7a, let-7c, and miRs 130a, 26b, 
467a, 30c, 100, 143, 200a, 454, 129-3p, 142-3p, 122a, 350, 450, and 301 were 
downregulated in K5 E2F1 epidermis.  The reason for the inconsistency between 
the Northern blot and microarray data for let-7 is unclear at this point.  However, it is 
worth noting that Bueno et al. recently confirmed regulation of the let-7 cluster by 
E2F1 and E2F3 (161).  It is also worth noting that attempts were made to confirm 
the microarray data for miR-301 and miR-15a, the miRNAs with the greatest fold 
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change, by northern blot.  However, these attempts were unsuccessful, possibly 
due to the lack of overall abundance of these miRNAs in skin. 
Finally, chromatin immunoprecipitation (ChIP) experiments were conducted 
to ascertain whether E2F1 directly regulates any of the identified miRNAs by 
binding to their respective promoters.  We found no evidence that let-7 was E2F1 
regulated, at least at the sites we examined.  However, ChIP experiments do show 
that E2F1 binds to the miR-301 promoter (Figure 3.5).  Further experiments are 
needed to confirm regulation of miR-301 by E2F1 and the physiological 
consequences of such a relationship.
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Figure 3.1.  Let-7a & c expression is increased in K5 E2F1 epidermis.  Skin 
from wildtype or K5 E2F1 transgenic mice was treated with DMBA/TPA or acetone 
vehicle (untreated).  RNA was isolated from the epidermis, run on a 15% PAGE gel 
and transferred to a nylon membrane.  Northern blotting was done with either a let-7 
miRNA or U6 snRNA specific probe.  Densitometry is shown for let-7a & c, 
respectively, compared to U6 as a loading control.  Northern blotting was done in 
duplicate. 
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Figure 3.2.  Ras levels are not significantly different than wildtype in K5 E2F1 
epidermis.  Epidermis from either wildtype or K5 E2F1 mice was treated with 
acetone (AC), acetone/TPA (AC/TPA) or DMBA/TPA.  Protein was isolated from 
whole skin by scraping, run on an 8% SDS/PAGE gel, and transferred to a PVDF 
membrane.  Antibodies were for Ras (recognizes H-, K-, and N-Ras) or -tubulin.  
Densitometry is shown. 
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Figure 3.3.  Ad-E2F1 expression does not affect Ras levels in cultured cells.  
Normal human fibroblasts (NHF) or CH72 keratinocytes were mock-infected (M) or 
infected with a control (C) or Ad-E2F1 adenovirus.  Protein was collected at 24, 36, 
and 48 hours.  Antibodies were for E2F1, Ras (recognizes H-, K-, and N-Ras), or 
Actin. 
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Figure 3.4.  K5 E2F1 transgenic epidermis differentially expresses certain 
miRNAs when compared to wildtype skin.  RNA was isolated from either 
wildtype (WT) or K5-E2F1 epidermis and analyzed using the Exiqon miRCURY 
LNA™ microRNA Array.   Results for differentially regulated murine miRNAs are 
shown as log2 ratio of Hy3/Hy5, which corresponds to fold change.  Hy3 and Hy5 
refer to fluorophores used to label each genotype.
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Figure 3.5.  E2F1 is found at the miR-301 promoter.  Chromatin 
immunoprecipitation (ChiP) was performed on NIH 3T3 cells using the Upstate 
Biotechnolgy kit.  Chromatin was immunoprecipitated with an E2F1 antibody, an 
IgG control, or no antibody (No Ab).  PCR was performed on 50 ng of DNA from 
each immunoprecipitation (IP) or input DNA using miR-301 specific primers.  PCR 
was performed in duplicate. 
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3.5 Discussion  
 
In this study, we investigated whether E2F1 could mediate control of miRNA 
expression in mouse epidermis.  We found several differentially regulated miRNAs 
between wildtype and K5 E2F1 transgenic epidermis each of which needs to be 
explored further.  Our data also confirms a report by others that E2F1 
overexpression regulates at least two isoforms of let-7, a and c, in mouse skin, the 
significance of which remains to be seen (161).  We could not however prove direct 
regulation of let-7 by E2F1 leaving open the possibility that intermediate signaling 
molecules exist between these two proteins. 
We also found that E2F1 binds the miR-301 promoter, though the 
significance of this finding is also unclear at this time, since little is known about the 
function of miR-301.  We do know that miR-301 is located in intron 1 of Ska2 and 
participates in a positive feedback loop with MEOX2 and the ERK/CREB pathway 
on Ska2 expression (162).  Ska2 is a member of the spindle and kinetochore 
complex and seems to be important for maintenance of the metaphase plate and 
spindle checkpoint (163).  So, it is possible that deregulation of miR-301 expression 
could result in chromosomal abnormalities.  Indeed, four reports have shown that 
miR-301 expression is differentially regulated between tumors and normal tissue of 
the pancreas, liver, bile duct, and lung.  However, whether miR-301 is up or down 
regulated seems to be tissue specific (164-167).  Also of note, miR-301 expression 
is decreased in p53-/- embryos, though this may be due to a decrease in miRNA 
processing which seems to be regulated by the p53 family (168).   
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In conclusion, we have now shown that at least some miRNAs are indeed 
regulated by E2F1 in mouse epidermis.  We have also shown that one of these 
miRNAs, miR-301, is a direct E2F1 target.  Given the diverse nature of these 
molecules it is likely that some miRNAs identified by us will be proven important in 
epithelial cell homeostatic processes and possibly tumor development. 
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Chapter 4: The Role of E2F1 Serine 29 in the DNA Damage 
Response and Tumor Suppression 
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4.1 Abstract 
 
The transcription factor E2F1 is induced and stabilized in response to DNA damage 
through its phosphorylation at serine 31 by ATM and ATR, and subsequent 
interaction with 14-3-3 .  E2F1's phosphorylation also leads to its association with 
TopBP1 and localization to DNA damage-induced foci.  To study the role of E2F1 in 
the response to DNA damage, our lab has generated a unique mouse model in 
which serine 29 of E2F1 has been replaced by an alanine (S29A), preventing 
phosphorylation.  Initial experiments indicate that the E2F1 S29A protein is not 
stabilized in response to ionizing radiation (IR) and cannot localize to sites of DNA 
damage.  As well, mutation of S29 results in an accumulation of endogenous DNA 
damage, mimicking total E2F1 loss.  Additionally, there is a repair deficiency in 
E2f1S29A/S29A mutant cells as compared to wild type cells when exposed to either IR 
or neocarzinostatin (NCS).  Further, the viability of E2f1S29A/S29A MEFs is reduced, 
and higher levels of apoptosis are observed in response to UVB.  To further study 
the role of E2F1 serine 29 in the DNA damage response and tumorigenesis, mice 
are being aged to examine the formation of spontaneous tumors.  Previously, our 
lab has shown that E2F1 acts as a tumor suppressor in the K5 Myc transgenic 
mouse model.  To examine the importance of E2F1's ability to respond to Myc-
induced DNA damage in suppressing tumorigenesis, we have crossed the 
E2f1S29A/S29A knockin mouse onto a K5 Myc transgenic background and found no 
difference in tumor incidence with wildtype E2F1 or E2F1 S29A; yet tumor spectra 
and multiplicity vary slightly.  Skin studies examining proliferation in the skin of 
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these mutant mice indicate similarities to E2F1 knockout mice, while apoptosis 
appears to be lower in the E2f1S29A/S29A mutant than the knockout in response to 
Myc. Taken together, our data indicate a role for E2F1 at sites of DNA damage, 
which requires its phosphorylation at serine 29, and may promote DNA repair. 
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4.2 Introduction 
 
E2F1 is a member of the E2F family of transcription factors.  It is a multi-
faceted protein that has roles in a number of important cellular processes including 
cell cycle, apoptosis, proliferation, and the DNA damage response (DDR).  E2F1’s 
role in the DDR first emerged when it was shown that E2F1 protein levels increased 
in response to a variety of DNA damaging agents (169-172).  Subsequently, it was 
shown that stabilization of E2F1 is dependent on ATM activity.  In fact, E2F1 can be 
phosphorylated by ATM/ATR in response to DNA damage at serine 31 (29 in mice).  
Moreover, phosphorylation at this site is required for ATM-induced stabilization of 
E2F1 (173).  Yet, the mechanism of E2F1 stabilization was not worked out until 
later.  
 E2F1 is stabilized in response to DNA damage by the binding of 14-3-3 
which inhibits E2F1’s ubiquitination and degradation.  Binding of 14-3-3 to E2F1 
requires its phophorylation at serine 31 by ATM.  As well, 14-3-3 is required for the 
induction of the apoptosis inducing genes, p73, Apaf-1, and caspases by E2F1 in 
response to DNA damage (174).  Thus, the induction of apoptosis in response to 
DNA damaging agents is one function of E2F1. 
 Further studies have recognized a possible role for E2F1 at the actual sites 
of DNA damage.  A yeast two-hybrid screen identified TopBP1 (DNA topoisomerase 
II-binding protein I) as an E2F1 binding partner.  TopBP1 localizes to DNA damage-
induced foci after IR treatment along with other proteins implicated in the DDR, 
including BRCA1 and 53BP1 (175-177).  The first and second BRCT domains of 
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TopBP1 are important for binding DNA breaks (178).   The 6th BRCT domain of 
TopBP1 is important for interaction with E2F1, while the N-terminus of E2F1 is 
required for this interaction.  This interaction is unique to E2F1, induced by DNA 
damage, requires phosphorylation of E2F1 by ATM, and represses E2F1-induced 
transcription, S-phase entry, and apoptosis (179). 
 To study the role of E2F1 in the DNA damage response in vivo and its 
possible effects on tumorigenesis, we have developed a knockin mouse model 
where serine 29 of E2F1 is replaced by alanine.  This model allows us to study the 
DNA damage specific effects of E2F1 independent of its role in transcription, since 
E2F1’s role in the DDR requires its phosphorylation at S31 and our modified E2F1 
is still functional in transcription.  We found that E2F1 S29A is not stabilized in 
response to DNA damage and does not go to DNA damage induced foci.  As well, 
E2F1S29A/S29A cells accumulate endogenous DNA damage and are slower to repair 
than wildtype cells after NCS treatment.  Finally, K5 Myc, E2F1S29A/S29A mice have a 
different tumor spectrum, more tumors per mouse, and more aggressive tumors 
than K5 Myc mice with wildtype E2F1.  All of this points to a role for E2F1 in tumor 
suppression through its participation in the DNA damage response. 
 
4.3 Materials and Methods 
 
4.3.1 Mice:  K5 Myc mice were previously described (106, 107).  As well, E2f1-/- 
mice have been previously described (88, 89).  Both lines were maintained at ≥ 
95% pure FVB.  E2f1S29A/S29A mice were generated in our lab as follows.  The 
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mouse E2f1 locus was cloned into a vector after long-range PCR using isogenic 
129 ES cell DNA as a template.  A unique AviII site was introduced into exon 1 
upon site-directed mutagenesis using a kit from Stratagene (Agilent Technologies, 
Inc., Santa Clara, CA).  This mutagenesis also changed the protein coding 
sequence from a serine at position 29 to an alanine.  After homologous 
recombination, positive clones were identified by Southern blotting and injected into 
recipient females to generate two lines (1 & 2).  Chimeras from each line were bred 
with C57 Bl/6 females to confirm germline transmission and crossed to a FLPeR 
mouse (Stock # 003946, The Jackson Laboratory, Bar Harbor, ME) to remove the 
PGK selection cassette.  Resulting E2f1S29A/S29A mice on a mixed background were 
used for studies.  K5 Myc mice were crossed to E2f1S29A/+ mice to generate 
wildtype, K5 Myc, E2f1S29A/S29A knockin, and K5 Myc, E2f1S29A/S29A knockin mice.  
Mice were checked weekly for spontaneous tumor development. 
 
4.3.2 Immunohistochemistry:  IHC was performed according to the methods in 
Chapter 2 for BrdU and Caspase-3.  TUNEL was performed with the Tdt-FragEL 
DNA Fragmentation Detection Kit (QIAGEN, Valencia, CA).  Slides were 
deparaffinized and rehydrated in dH2O, incubated with 3% H2O2, and rinsed.  
Subsequently, slides were incubated with proteinase K (20 µg/ml) for 20 minutes, 
rinsed in dH2O followed by PBST.  Next, slides were equilibrated in Tdt equilibration 
buffer for 10-30 minutes and incubated with Tdt labeling reaction buffer for 1 hour at 
37°C.  After rinsing in PBST, stop buffer was added for 5 minutes.  Following 
another PBST wash, tissue was blocked for 10 minutes in blocking buffer.  
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Conjugate was added for 30 minutes; slides were rinsed with PBST and developed 
with DAB. 
 
4.3.3 Comet Assay:  The comet assay, or single cell gel electrophoresis (SCGE) 
assay, was performed using the assay kit from Trevigen, Inc. (Gaithersburg, MD).  
Briefly, after treatment (NCS, 100 ng/ml), cells were harvested and embedded in 
low melting point agarose on glass slides and incubated overnight at 4oC in lysis 
buffer.  Mouse adult fibroblasts (MAFs) were subjected to the neutral assay, while 
keratinocytes were processed with the alkaline method.  For the alkaline assay, 
slides were incubated in alkaline buffer (200 mM NaOH, 1 mM EDTA) before 
electrophoresis; while for the neutral assay, this step was skipped.  After washing, 
samples were electrophoresed at 19 volts for 5-20 minutes in TBE.  Following 
fixation and drying, cells were stained with SYBR Green.  Nuclei were visualized 
and images captured using a fluorescent microscope.  Olive moment of at least 95 
nuclei per slide was calculated using COMETSCORE software (Tritek Corp., 
Sumerduck, VA). 
 
4.3.4 Chromatin Immunoprecipitation:  ChIP was performed essentially as in 
Chapter 3 Materials & Methods.  MAFs were generated from wildtype or 
E2f1S29A/S29A knockin mice using standard procedures.  MAFs were infected with an 
I-Ppo 1 expressing retrovirus, induced with tamoxifen (1 M), and collected 8 hours 
later.  PCR was performed using primers specific to the chromosome 10 I-Ppo 1 cut 
site. 
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4.3.5 Immunofluorescence:  Cells were fixed after IR treatment or Ad-Myc 
infection to induce double-strand breaks, DSBs.  For immunofluorescent staining, 
fixed cells were incubated with 3% BSA, washed, and then incubated with 
appropriate primary antibodies, E2F1 (C20, sc-193 (1:50) or KH95, sc-251 (1:50), 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or H2AX (BL179 (1:4000), Bethyl 
Laboratories, Montgomery, TX; 05-636 (1:4000), Millipore, Billerica, MA).  Following 
incubation with a fluorescently tagged secondary antibody (A-11037 or A-11029 
(1:400), Invitrogen Corporation, Carlsbad, CA), slides were stained with DAPI and 
coverslipped before visualization.  Appropriate fluorescent images were captured 
using a Nikon eclipse 80i microscope equipped with an X-cite 120 fluorescence 
illumination system and Metamorph image analysis software. 
 
4.4 Results 
 
In order to study the role of E2F1 in the DNA damage response, independent 
of its role in transcription, we have generated E2f1S29A/S29A knockin mice (Figure 
4.1). Two independent ES cell clones were used to generate chimeras that were 
then bred to homozygosity.  These mice carry a single amino acid substitution at 
position 29 (31 in humans) of the E2F1 gene resulting in the exchange of serine for 
alanine.  This results in a protein incapable of being phosphorylated at this position.  
However, we could not independently verify lack of phosphorylation because no 
antibody could be raised to specifically identify this mutant.  Nevertheless, we are 
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confident that phosphorylation is inhibited based on the well accepted function of 
serine to alanine mutants and the biochemical phenotypes we observed.    
E2f1S29A/S29A knockin mice are phenotypically similar to wildtype mice and 
develop normally.  We have yet to observe the phenotypic abnormalities observed 
in E2f1-/- mice including testicular atrophy, exocrine gland hyperplasia, and 
defective thymocyte apoptosis (87, 88).  We did observe that E2f1S29A/S29A mice 
have lower body weights than wild type mice on a mixed background, although this 
difference is not significant, p=.065 at 45 weeks (Figure 4.2). 
In contrast to the lack of noticeable physical defects, E2f1S29A/S29A mice have 
significant defects in the biochemical activities of the E2F1 protein.  First, E2F1 
S29A cannot be stabilized in response to ionizing radiation (IR) unlike wildtype 
E2F1 (Figure 4.3).  As well, the E2F1 S29A mutant cannot form foci in response to 
IR or go to sites of DNA double strand breaks as assayed by ChIP (Figure 4.4 and 
4.5).  Additionally, there is increased endogenous DNA damage in E2f1S29A/S29A 
keratinocytes as compared to wildtype, p=1 x 10-7.  In fact, mutation of serine 29 to 
alanine results in the same amount of endogenous DNA damage as complete E2F1 
loss (Figure 4.6).  Finally, E2f1S29A/S29A MAFS exposed to the DNA double strand 
break inducing agent, neocarzinostatin, repair their DNA less efficiently that wildtype 
cells exposed to the same conditions (Figure 4.7).  All of these data point to a 
significant role for E2F1 in the DNA damage response and DNA repair that requires 
phosphorylation at serine 29. 
Our lab previously identified E2F1 as a tumor suppressor in response to the 
c-Myc oncogene (107).  As well, we reported that K5 Myc overexpression results in 
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DNA damage-induced foci in transgenic skin (180).  We now show that E2F1 loss 
also causes DNA damage in primary keratinocytes, p=2.85 x 10-13.  This damage is 
more than K5 Myc expression, p=0.003.  When both conditions are present there is 
a slight overall increase in DNA damage as compared to the non-transgenic, though 
this is not significant (Figure 4.8).     
To study the effects of E2F1’s ability to function in the DNA damage 
response on K5 Myc-induced hyperplasia and apoptosis, we crossed E2f1S29A/S29A 
onto a K5 Myc background.  We first took skin from E2f1+/+, E2f1S29A/S29A, K5 Myc, 
and K5 Myc, E2f1S29A/S29A mice and stained for BrdU incorporation, TUNEL, and 
caspase-3 activity.  The skin study showed no difference in proliferation or 
apoptosis in the presence of K5 Myc expression whether E2F1 was wildtype or 
mutant (Figure 4.9).  This is different than what was observed in E2f1-/- mice, which 
had increased levels of apoptosis in a K5 Myc transgenic background (107).  We 
did, however, identify a difference between wildtype and E2f1S29A/S29A skin in 
caspase-3 activity, p=0.04, though both genotypes had very low levels of apoptosis.   
K5 Myc, E2f1S29A/S29A mice were allowed to age to examine the effects of 
E2F1 S29A mutation on K5 Myc-induced tumorigenesis.   Spontaneous tumor 
studies show there is no significant difference in tumor incidence in response to K5 
Myc when E2F1 serine 29 is mutated to alanine (Figure 4.11).  The tumor incidence 
is 26% in K5 Myc mice versus 17% in K5 Myc, E2f1S29A/S29A by one year of age.  
This rate of tumor incidence is consistent with what we previously reported for K5 
Myc mice (107, 180).  However, at 70 weeks, the tumor incidence is 100% in K5 
Myc mice versus 73% in K5 Myc, E2f1S29A/S29A, though this is not significant with the 
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amount of mice in this study.  Despite this, tumor spectrum and the number of 
tumors per mouse, seem to vary slightly when E2F1 is mutated.  One K5 Myc, 
E2f1S29A/S29A mouse developed a squamous cell carcinoma within the skin of 
unknown origin, possibly arising from the skin adnexae.  Also, two K5 Myc, 
E2f1S29A/S29A mice developed multiple tumors.  One mouse developed 3 squamous 
cell carcinomas and the other 2 papillomas.  This is in contrast to K5 Myc mice, 
which do not develop multiple tumors.  As well, one K5 Myc, E2f1S29A/S29A mouse 
with an odontogenic tumor showed evidence of metastasis to the lungs, again 
something not seen in K5 Myc mice, suggesting an increase in aggressiveness of 
tumors lacking a functional E2F1.  Finally, we found that E2F1 localizes to foci when 
DNA is damaged by Ad-Myc overexpression (Figure 4.10).  Taken together, these 
data suggest a role for E2F1 in responding to Myc-induced damage, which may 
affect tumor multiplicity and aggressiveness. 
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Figure 4.1.  Knockin scheme for E2f1 S29A mice.  Wildtype and knockin (KI) 
alleles are shown.  Expected band sizes after digestion with BamHI and AviII are 
also shown, 14.6 Kb for wildtype and 6 Kb for KI.  Targeted ES cell clones are 
shown after Southern blot.  A unique AviII site was introduced by site-directed 
mutagenesis into the KI allele.  A PGK-Neo cassette flanked by FRT sites was used 
for selection in ES cells and later removed by breeding to a FLPer mouse.
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Figure 4.2. E2f1S29A/S29A mice have lower body weights than E2f1+/+ mice on a 
mixed background.  Starting at 34 weeks of age, E2f1+/+ and E2f1S29A/S29A female 
mice were weighed weekly until one year of age.  Weight in grams is shown.  The 
number of mice (n=3 to n=10) varies week to week depending on available mice in 
age group.  p=.065 at 45 weeks. 
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Figure 4.3. E2F1 S29A is not stabilized in response to ionizing radiation.  
Mouse adult fibroblasts (MAFs) were isolated from either E2f1+/+ or E2f1S29A/S29A 
mice.  Cells were exposed to 6 Grey of ionizing radiation and protein collected at 
the indicated time points.  Antibodies were for E2F1 or GAPDH as a loading control.  
h=hours 
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Figure 4.4. E2F1 S29A does not go to DNA double strand breaks induced by 
ionizing radiation.  Mouse embryonic fibroblasts (MEFs) were isolated from d13.5 
embryos.  After no treatment or treatment with 5 Grey (Gy) of ionizing radiation (IR), 
cells were fixed and stained for E2F1.  Fluorescent images are shown (A).  
Percentage of cells with E2F1 foci is shown in (B). 
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Figure 4.5. E2F1 S29A does not go to sites of DNA damage induced by I-Ppo-
1.  Mouse adult fibroblasts from E2f1+/+ or E2f1S29A/S29A mice were infected with an I-
Ppo-1 expressing retrovirus.  After induction with tamoxifen, double strand breaks 
were generated at I-Ppo-1 recognition sites.  ChIP assay is shown with (+) and 
without (-) I-Ppo-1 infection using E2F1, phospho-ATM, and normal IgG antibodies.  
PCR was performed using primers that specifically amplify the I-Ppo-1 site on 
chromosome 10.   
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Figure 4.6.  Mutation of E2F1 S29A results in endogenous DNA damage 
equivalent to total E2F1 loss.  Primary keratinocytes from E2f1+/+, E2f1S29A/S29A, 
and E2f1-/- were subjected to the comet assay.  After electrophoresis, cells were 
fixed and stained with SYBR green.  At least 150 cells per genotype were analyzed 
with the COMETSCORE software.  Olive moment, the product of tail length and 
fraction of total DNA in the tail, is shown  standard error.  * represents p<5x10-6 by 
t-test.
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Figure 4.7. E2f1S29A/S29A cells repair DNA damage less efficiently than E2f1+/+ 
cells.  Mouse adult fibroblasts (MAFs) from E2f1+/+ or E2f1S29A/S29A mice were 
treated with neocarzinostatin (NCS) for 30 minutes and collected at 1 hr, 6 hr, and 
24 hr post treatment.  MAFs were then subjected to the neutral comet assay.  A 
minimum of 95 cells per genotype and time point, were analyzed with the 
COMETSCORE software.  The average Olive moment, the product of the tail length 
and the fraction of total DNA in the tail, is shown  standard error.  * indicates 
p<0.01 by t-test within each time point.
 75 
 
Figure 4.8.  K5 Myc and E2F1 loss cause DNA damage in primary cells. 
Primary keratinocytes from E2f1+/+; K5 Myc; E2f1-/-; and K5 Myc, E2f1-/- mice were 
subjected to the alkaline comet assay.  After electrophoresis, cells were fixed and 
stained with SYBR green.  At least 95 cells per genotype were analyzed with the 
COMETSCORE software.  Average Olive moment is shown  standard error.  The 
asterisk(s) represents p<0.004 by t-test. 
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Figure 4.9. E2F1 S29A does not affect proliferation or apoptosis in response 
to K5 Myc.  Epidermis from E2f1+/+, E2f1S29A/S29A, K5 Myc, and K5 Myc, 
E2f1S29A/S29A mice was collected and analyzed for proliferation and apoptosis.  
Averages of at least 5 mice per genotype are shown. (A) shows the percentage 
BrdU incorporation per 1000 basal cells.  (B) shows TUNEL staining.  (C) is 
Caspase-3 immunohistochemistry.  Both (B) and (C) are the number of cells per 10 
mm of epidermis.  Asterisk(s) indicate p<0.05 by t-test.
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Figure 4.10.  E2F1 goes to sites of DNA damage induced by Ad-Myc infection.  
Immortalized normal human fibroblasts were serum starved for 24 hours and then 
infected with an Ad-Myc adenovirus or mock-infected.  Forty-eight hours after 
infection, cells were subjected to immunofluorescence with an E2F1 and H2AX 
antibody.  Representative images are shown. 
 
 
 
 78 
 
 
 
Figure 4.11. E2F1 S29A does not change K5 Myc-induced tumor incidence on 
a mixed background.  K5 Myc and K5 Myc, E2f1S29A/S29A mice on a mixed 
background were aged for spontaneous tumorigenesis.  The percentage of mice 
with K5 tumors versus age in weeks is shown.   
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4.5 Discussion 
 
In this report we have examined the role of E2F1 in the DNA damage 
response and tumorigenesis using a unique knockin mouse model in which E2F1 
serine 29 is mutated to alanine.  These mice develop normally, with only a slightly 
decreased body mass, and lack the characteristic testicular atrophy, exocrine gland 
hyperplasia and defects in thymocyte apoptosis seen in E2f1-/- mice (87, 88).  Since 
our model only affects E2F1 activities mediated by phosphorylated S29, it is 
probable that these defects seen in E2f1-/- mice are due to non-functional E2F1 
transcriptional activity. 
When we examined E2f1S29A/S29A mice biochemically, we made some 
interesting observations.  E2F1 S29A protein cannot be stabilized in response to 
DNA damage, nor can it localize to DNA damage-induced foci suggesting it cannot 
interact with 14-3-3 or TopBP1.  As well, cells isolated from E2f1S29A/S29A mice have 
high levels of endogenous DNA damage and a defect in DNA repair.  These data 
suggest a role for E2F1 in maintaining genomic stability that requires its function at 
DNA damage sites. 
Finally, we report on the role of E2F1 in response to transgenic Myc 
expression.  We found that mutation of serine 29 to alanine did not affect overall 
tumor incidence in K5 Myc mice.  However, a unique tumor type was identified in K5 
Myc, E2f1S29A/S29A mice that possibly arose from the skin adnexae.  Several K5 Myc, 
E2f1S29A/S29A mice also developed more than one tumor, a finding that was unique to 
this genotype.  In fact, one mouse had 3 squamous cell carcinomas.  Consequently, 
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this mouse also had fight wounds from its littermates.  One hypothesis is that 
wounding promoted the formation of these tumors.  Lastly, we found evidence of 
metastasis in the lungs of a K5 Myc, E2f1S29A/S29A mouse with an odontogenic 
epithelial tumor.  Taken together, these data point to a role for E2F1 in suppressing 
Myc-induced tumorigenesis that requires its phosphorylation at serine 29. 
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Chapter 5:  Future Directions, Summary, and Implications 
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5.1 Future Directions 
 
5.1.1 The Role of p21 and Senescence in Tumor Suppression by the E2F1 
Transcription Factor 
 
 In the second chapter, we explored the idea that tumor suppression by E2F1 
overexpression could be mediated through the cell cycle inhibitor p21 and its ability 
to induce senescence.  We found that ARF, p53, and p21 levels are all increased in 
K5 E2F1 epidermis, and loss of ARF inhibits this increase in p53 and p21.  
Additionally, hyperplasia increases in the absence of ARF in K5 E2F1 transgenic 
mice, but not apoptosis, both after treatment with chemical carcinogens.  
Conversely, when p21 is lost, there is a decrease in hyperplasia, and increased 
proliferation and apoptosis.   
We next performed two-stage carcinogenesis assays.  Our original studies 
showing K5 E2F1 mice are resistant to two-stage chemical carcinogenesis in an 
ARF and p53-dependent manner were done in an SSIN background.  So, we first 
checked the ability of K5 E2F1 to suppress tumorigenesis on an FVB background.  
We found that K5 E2F1 was indeed still tumor suppressive on an FVB background.  
However, we could not determine whether p21 status affected tumor suppression 
by E2F1 since all p21-null mice were resistant to two-stage chemical 
carcinogenesis.  Finally, we examined senescence in K5 E2F1 epidermis by -
galactosidase staining.  We found high levels of background staining in FVB mice, 
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which precluded a conclusion about senescence in E2F1-mediated tumor 
suppression.  
To expand on these findings, it would be interesting to repeat the tumor 
studies of p21-null mice using the original background strain, SSIN.  Given the 
results of Topley et al who conducted chemical carcinogenesis studies on p21-null 
mice in a similar background strain, we would expect the K5 E2F1, p21-/- mice in 
this strain to be sensitive to DMBA/TPA treatment.  This strain would also allow us 
to stain for senescence using -galactosidase.  It is likely that we would find that 
senescence is mediated by p21 in response to K5 E2F1.  On the other hand, if we 
were to repeat the two-stage studies in an FVB background for the K5 E2F1, ARF-/- 
and K5 E2F1, p53-/- mice, it is possible that we would get different results.   
  
5.1.2 E2F1-mediated regulation of miRNAs 
 
 In the third chapter, we questioned whether E2F1 could regulate the 
expression of miRNAs, and in turn if miRNAs could mediate tumor suppression by 
the E2F1 transcription factor.  We identified a total of 22 miRNAs that are 
differentially regulated between wildtype and K5 E2F1 transgenic epidermis.  Of 
these, let-7a & c were shown to be upregulated in K5 E2F1 transgenic epidermis by 
northern blot.  Further, let-7a & c expression increased even more upon treatment 
with chemical carcinogens in both wildtype and K5 E2F1 skin.  However, even 
though let-7 has been identified as a negative regulator of Ras, we could find no 
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downstream consequences of let-7 expression on the Ras signaling pathway.  
Additionally, we found that E2F1 binds the miR-301 promoter. 
 The future directions for this project should first be to resolve the conflict that 
exists between the northern blot and microarray results concerning let-7 expression.  
Both assays should be repeated, along with realtime PCR using RNA from both 
wildtype and K5 E2F1 epidermis.  Next, the finding that E2F1 binds the miR-301 
promoter should be followed up on.  Possible experiments include a luciferase 
reporter assay using the miR-301 promoter to determine if E2F1 affects miR-301 
expression.  Realtime PCR should be conducted as well.  The miR-301 target, 
Ska2, should be investigated to see if E2F1 affects its expression by western blot or 
vice versa.  As well, the tissue types that have been reported to have differential 
expression of miR-301 between normal and tumor samples should be analyzed for 
E2F1 expression.  Further, miR-301 expression should be checked in E2f1-/- or 
siRNA knockdown cell lines.  Finally, the 22 miRNAs identified by microarray should 
all be validated individually by northern blot and realtime PCR.  
 
5.1.3 The Role of E2F1 Serine 29 in the DNA Damage Response and Tumor 
Suppression 
 
 In this final group of experiments, we asked whether E2F1’s role in the DNA 
damage response could mediate its tumor suppressive properties.  We found 
E2f1S29A/S29A mice were phenotypically normal except for a slighty lower body 
weight.  As well, the E2F1 S29A mutant protein cannot be stabilized in response to 
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DNA damage, nor can it localize to sites of damage. E2f1S29A/S29A keratinocytes and 
MAFs have increased endogenous DNA damage compared to wildtype cells, and 
E2f1S29A/S29A MAFs do not repair as efficiently as their wildtype counterparts.  In 
response to Myc, tumor incidence is not changed when E2F1 is mutated.  However, 
tumor spectrum, tumor multiplicity and aggressiveness seem to be modulated by 
E2F1’s ability to respond to DNA damage. 
 Future experiments should focus on the findings concerning tumor spectrum, 
aggressiveness, and multiplicity.  The tumor of questionable origin should be 
stained for various epithelial markers, such as keratins, to determine where it 
originated.  As well, immunohistochemistry can be used to stain for markers 
associated with metastasis such as the MMPs (matrix metalloproteases), or Slug 
and Snail.  Another interesting angle to pursue would be a wounding study.  Given 
that the only K5 Myc, E2f1S29A/S29A mouse with multiple SCCs also had fight 
wounds, it reasonable to assume that the inflammation associated with those 
wounds might have served as a tumor promoter.  Further biochemical studies (co-
immunoprecipitations) can be conducted as well to determine which proteins E2F1 
might be interacting with at DNA damage sites and how this interaction may affect 
repair. 
 
5.2 Summary and Implications 
  
In these studies we examined three mechanisms by which E2F1 might 
mediate its tumor suppressive properties:  p21-induced senescence, miRNAs, and 
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the DNA damage response.  When overexpressed, we found that E2F1 acts as a 
tumor suppressor in response to ras activation through a non-apoptotic mechanism 
requiring ARF and p53, but not p21.  Additionally, we provided intriguing evidence 
that E2F1 is involved in miRNA regulation.  And finally, our data indicates a role for 
E2F1 at sites of DNA damage, which may promote DNA repair and requires its 
phosphorylation at serine 29.  These studies have identified proteins and signaling 
pathways that are important in tumor suppression.  Ultimately, this information can 
be used in the future to develop drugs that may target these proteins and pathways 
and may be used in cancer treatment. 
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